Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

892 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Dougados M, Emery P, Gibofsky A, Kavanaugh AF, Keystone EC, Klareskog L, Russell AS, van de Putte LB, Weisman MH. Furst DE, et al. Among authors: burmester gr. Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii2-9. doi: 10.1136/ard.62.suppl_2.ii2. Ann Rheum Dis. 2003. PMID: 14532138 Free PMC article. Review. No abstract available.
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
Burmester GR, Mariette X, Montecucco C, Monteagudo-Sáez I, Malaise M, Tzioufas AG, Bijlsma JW, Unnebrink K, Kary S, Kupper H. Burmester GR, et al. Ann Rheum Dis. 2007 Jun;66(6):732-9. doi: 10.1136/ard.2006.066761. Epub 2007 Feb 28. Ann Rheum Dis. 2007. PMID: 17329305 Free PMC article. Clinical Trial.
Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester GR; Research in Active Rheumatoid Arthritis (ReAct) Study Group. Bombardieri S, et al. Among authors: burmester gr. Rheumatology (Oxford). 2007 Jul;46(7):1191-9. doi: 10.1093/rheumatology/kem091. Epub 2007 May 15. Rheumatology (Oxford). 2007. PMID: 17504821 Clinical Trial.
An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status.
van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, Beckmann C, Unnebrink K, Kupper H. van der Bijl AE, et al. Among authors: burmester gr. Clin Rheumatol. 2008 Aug;27(8):1021-8. doi: 10.1007/s10067-008-0866-4. Epub 2008 Mar 19. Clin Rheumatol. 2008. PMID: 18350329 Free PMC article. Clinical Trial.
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).
Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman DD, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen JS. Antoni CE, et al. Among authors: burmester gr. J Rheumatol. 2008 May;35(5):869-76. Epub 2008 Mar 15. J Rheumatol. 2008. PMID: 18381786 Clinical Trial.
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, Strand V, Vencovsky J, van der Heijde D. Smolen J, et al. Among authors: burmester gr. Ann Rheum Dis. 2009 Jun;68(6):797-804. doi: 10.1136/ard.2008.101659. Epub 2008 Nov 17. Ann Rheum Dis. 2009. PMID: 19015207 Free PMC article. Clinical Trial.
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
Strand V, Mease P, Burmester GR, Nikaï E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A. Strand V, et al. Among authors: burmester gr. Arthritis Res Ther. 2009;11(6):R170. doi: 10.1186/ar2859. Epub 2009 Nov 12. Arthritis Res Ther. 2009. PMID: 19909548 Free PMC article. Clinical Trial.
892 results